August 12, 2026, CKI HOLDINGS(01038.HK) released its Interim Report for the period ended December 31, 2026, Total Revenue stood at HKD 2.07 billion, decreased by 6.16% YoY
August 12, 2026, POWER ASSETS(00006.HK) released its Interim Report for the period ended December 31, 2026, Total Revenue stood at HKD 298 million, decreased by 15.34% YoY
August 12, 2026, CHANGHONG JH(03991.HK) released its Interim Report for the period ended December 31, 2026, Total Revenue stood at HKD 27.78 billion, increased by 31.24% YoY
August 12, 2026, DMALL(02586.HK) released its Interim Report for the period ended December 31, 2026, Total Revenue stood at CNY 1.15 billion, increased by 7.05% YoY
NewTimeSpace News: Impression Dahongpao announced on 12 August that for the six-month period ending 30 June 2026, total revenue is expected to reach approximately RMB47.1 million, representing a year-on-year decline of around 15.9%; net profit attributable to parent is estimated at roughly RMB2.5 million, falling by about 75.1% year-on-year.
NewTimeSpace News: XIMEI RESOURCES announced on 12 August that profit attributable to shareholders for the six-month period ending 30 June 2026 is expected to be approximately RMB163.9 million to RMB200.3 million, a notable increase from around RMB91.8 million in the corresponding period last year.
NewTimeSpace News: China Aluminum Cans announced on 12 August that net profit attributable to equity holders of the Company for the six-month period ending 30 June 2026 is expected to increase by more than 30% compared with the same period last year.
NewTimeSpace News: CSPC Pharmaceutical Group announced on 12 August that pursuant to the collaboration, option and licence agreement with AstraZeneca for siRNA drug development, the Group received the US$30 million upfront payment from AstraZeneca on 12 August 2026.
NewTimeSpace News: New City Development Group announced on 12 August that Li Yang has been appointed Co-Chief Executive Officer of the Company, and Han Junran has been re-designated from Chief Executive Officer to Co-Chief Executive Officer, with effect from 12 August 2026.
NewTimeSpace News: On 12 August 2026, Oriental Explorer Holdings Limited(00430.HK) issued a profit warning. Consolidated profit attributable to shareholders for the interim period is expected to decline to approximately HK$3,000,000 to HK$3,200,000 (compared with around HK$4,300,000 in the corresponding period of 2025), mainly due to lower rental income from commercial and industrial properties. Nevertheless, the Group’s overall financial position remains sound.
NewTimeSpace News: On 12 August 2026, V.S. INT'L (01002.HK) issued a positive profit warning, expecting an interim profit of USD 3,000,000-4,000,000 (versus approximately USD 900,000 in the same period of 2025) and a profit attributable to owners of USD 2,000,000-3,000,000, mainly due to business expansion, higher rental income and lower selling expenses.
NewTimeSpace News: On 12 August 2026, HENGRUI PHARMA (01276.HK) disclosed that its subsidiary Guangdong Hengrui received the Drug Clinical Trial Approval Notice for SHR-7590 Injection, approving clinical trials for ulcerative colitis and Crohn's disease; the drug is an in-house developed therapeutic biologic with no same-target drug approved globally, and cumulative R&D investment of approximately RMB 32.5 million.
NewTimeSpace News: On 12 August 2026, CAPINFO (01075.HK) issued a profit warning, expecting an interim loss attributable to equity shareholders of approximately RMB 30-50 million, swinging from a profit of RMB 9.54 million in the same period of 2025, mainly due to higher fulfillment costs, increased R&D investment and the one-off impact of a RMB 52.79 million liquidation gain recognized last year.
NewTimeSpace News: On 12 August 2026, CH TIANBAO GP (01427.HK) issued a profit warning, expecting its interim net loss to widen to RMB 60.0-70.0 million from RMB 37.3 million in the same period of 2025, mainly due to reduced revenue from fewer construction contracts following proactive control of undertaking scale and lower average selling prices of buildings.
NewTimeSpace News: On 12 August 2026, MULTIFIELD INTL (00898.HK) issued a profit warning. Consolidated profit attributable to shareholders for the interim period is expected to range from approximately HK$100 million to HK$120 million (versus around HK$238 million in the corresponding period of 2025). The decline is mainly driven by a drop in net fair value gains on financial assets at fair value through profit or loss from roughly HK$208 million to about HK$46 million, representing a non-cash movement.
NewTimeSpace News: On 12 August 2026, HENGRUI PHARMA (01276.HK) disclosed that HRS-4729 Injection, an in-house developed GLP-1R/GIPR/GCGR tri-agonist polypeptide, received NMPA approval for a Phase II clinical trial in adult type 2 diabetes patients, with a Phase II trial for weight loss also being advanced, and cumulative R&D investment of approximately RMB 81.6 million.
